Plain-English translation of NCT03391466 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lymphoma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial studied whether , a personalized cell therapy that reprograms a patient's own immune cells to fight cancer, was more effective than standard chemotherapy for people with diffuse large B-cell lymphoma that had come back or stopped responding to initial treatment. The study involved 359 patients who were randomly assigned to receive either the new cell therapy or conventional chemotherapy. Researchers followed participants for up to 5 years to see how well this medication worked compared to standard options.
When aggressive lymphoma returns after initial treatment or stops responding to it, patients have limited options and outcomes are often poor. This trial aimed to determine whether this new cell-based approach could offer better results and potentially transform how doctors treat patients in this difficult situation.
Participants were randomly assigned to one of two treatment groups. Those receiving the new cell therapy underwent three days of conditioning chemotherapy followed by an infusion of their own reprogrammed immune cells designed to target their lymphoma. Those receiving standard care received two to three cycles of conventional chemotherapy regimens. All participants were monitored during a treatment period and then followed for up to 5 years after treatment ended, with some participants continuing in a longer-term study for up to 15 years total to track their response and recovery.
AI-generated summary from trial data · Aug 28, 2026 · Not medical advice
United States